Publications by authors named "Anjali Suryavanshi"
MEK inhibitors in oncology: a patent review and update (2016 - present).
Expert Opin Ther Pat
October 2024
Introduction: Mitogen-activated protein kinase (MEK) is one of the important components of Ras/Raf/MEK/ERK signaling pathway, transduces signal for cell growth, differentiation, and development. Deregulation of MEK leads to a wide variety of cancer; hence, MEK is considered as potential therapeutic targets for the treatment of cancer. The MEK1/2 inhibitors in combination with other inhibitors showed better therapeutic outcomes in various malignancies including resistant or relapsed or refractory cancer.
View Article and Find Full Text PDFArticle Synopsis
- Alzheimer's Disease (AD) is a neurodegenerative disorder affecting 60-70% of dementia patients, primarily caused by misfolded proteins like β-amyloid and tau in the brain.
- Diagnostic imaging, such as amyloid PET and MRI, helps identify biomarkers linked to AD, guiding researchers in developing new treatments.
- Current medications, including acetylcholinesterase inhibitors and memantine, manage symptoms but do not reverse the disease; new therapies, like aducanumab and drugs in clinical trials, focus on removing amyloid proteins but require further research for effectiveness and safety.